Day: January 27, 2025

Los Angeles, CA, Jan. 27, 2025 (GLOBE NEWSWIRE) — Los Angeles, CA , January 27, 2025 (GLOBE NEWSWIRE)- KRONOS ADVANCED TECHNOLOGIES, INC. (OTC MARKETS: KNOS) (“KNOS” or the “Company”), a leader in innovation-driven air sterilization technologies, is pleased to share updates on the ownership structure and strategic goals for its subsidiary, KronosMD, Inc., as the company advances its mission to revolutionize dental and digital health technologies in 2025. Ownership and Structure Kronos Advanced Technologies Inc. owns all common shares and maintains full voting control of KronosMD Inc. Additionally, KronosMD’s preferred shareholders collectively hold over 5,000,000 shares with a par value of $1 per share. These shares were primarily issued to acquire groundbreaking dental imaging technologies, now rebranded as S-WAVE™ technology. KronosMD...

REYKJAVIK, Iceland and PARSIPPANY, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Biologics License Applications (BLA) for AVT05, Alvotech’s proposed biosimilar to Simponi® and Simponi Aria® (golimumab), which are prescribed to treat a variety of inflammatory conditions. These are the first U.S. BLA filing acceptances announced for a biosimilar candidate to golimumab. The FDA review process for these applications is anticipated to be completed in the fourth quarter of 2025. “This is a significant...

REYKJAVIK, Iceland and PARSIPPANY, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Biologics License Applications (BLA) for AVT05, Alvotech’s proposed biosimilar to Simponi® and Simponi Aria® (golimumab), which are prescribed to treat a variety of inflammatory conditions. These are the first U.S. BLA filing acceptances announced for a biosimilar candidate to golimumab. The FDA review process for these applications is anticipated to be completed in the fourth quarter of 2025. “This is a significant...

Designed to Prevent “Creeping” Control by 30% Shareholder and Protect the Long-Term Value for All Shareholders HONOLULU, Jan. 27, 2025 (GLOBE NEWSWIRE) — Barnwell Industries, Inc. (NYSE American: BRN) (“Barnwell” or the “Company”) today announced that the Board of Directors (the “Board”) of Barnwell has adopted a limited-duration shareholder rights plan (“Rights Plan”) designed to protect the interests of the Company and all of its shareholders. The Rights Plan is also intended to provide the Board sufficient time to make informed judgments and take actions that are in the best interests of Barnwell and all of its shareholders. The Rights Plan was adopted in response to the significant ownership position of Ned Sherwood and his affiliates (the “Sherwood Group”), which, based on public records, is approximately 30.00% of Barnwell’s...

ALMATY, Kazakhstan, Jan. 27, 2025 (GLOBE NEWSWIRE) — Kaspi.kz (KSPI US) will report its financial results for the quarter and year ended December 31, 2024, on Monday, 24th February, 2025. On that day, management will hold a conference call and webcast at 8.00am EST (1pm GMT, 6.00pm Astana time) to review and discuss the company’s results for the period. 4th Quarter & FY 2024 Financial Results Conference Call Monday, 24th February, 2025 To pre-register for this call, please go to the following link: https://www.netroadshow.com/events/login?show=ba8cfc64&confId=77130 You will receive your access details via email. About Kaspi.kz Kaspi.kz’s mission is to improve people’s lives by developing innovative mobile products and services. To deliver upon this we operate a unique two-sided Super App model – Kaspi.kz Super...

Nasdaq CopenhagenEuronext DublinLondon Stock ExchangeDanish Financial Supervisory AuthorityOther stakeholders Date        27 January 2025 Share buyback programme – week 4 The share buyback programme runs in the period 1 February 2024 up to and including 27 January 2025, see company announcement of 31 January 2024. Part I of the programme, for DKK 750 million, was completed on 27 June 2024, see company announcement of 28 June 2024. Part II of the programme, for DKK 775 million and a maximum of 1,550,000 shares, is for execution in the period 28 June 2024 – 27 January 2025. The programme is implemented in compliance with EU Commission Regulation No. 596/2014 of 16 April 2014 and EU Commission Delegated Regulation No. 2016/1052 of 8 March 2016, which together constitute the “Safe Harbour” rules. The following transactions have...

Oslo, January 27, 2025: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, invites to a webcast presentation of its fourth quarter 2024 results, on Friday, January 31, 2025. The presentation can be followed as a live webcast accessed through a link on www.ultimovacs.com at 09:00 CET on Friday, January 31, 2025. The webcast presentation will be available on the Ultimovacs website, and it will be possible to post questions during the presentation through the webcast. Note that the webcast presentation has been rescheduled from February 13, 2025, due to the ongoing business combination with Zelluna Immunotherapy AS, in order to fulfill regulatory requirements associated with this process. The report and presentation will be available on the company website from...

24 January 2025 Šiaulių Bankas AB (the Bank) has completed its own share buy-back programme on the regulated market, which was carried out from 4 November 2024. During this period, the Bank acquired 5,092,863 treasury shares, i.e. 74 % of the maximum number of shares within the limit set at the time of the programme’s expiry, for a total amount of EUR 4,345,207.01 million, at an average price of EUR 0.853 per share. “We are the first bank in the Baltic market to implement an open market buy-back programme for its own shares. The successful implementation of this programme has increased the Bank’s attractiveness to investors by increasing the liquidity of its shares on the stock exchange and the return to shareholders. In the long term, we plan to continue to optimise and efficiently manage the Bank’s capital in...